Men with high-risk prostate cancer have a higher likelihood of residual disease after prostatectomy and may require radiation ...

A prespecified analysis of a phase 3 trial evaluated the ability of PAM50 molecular prostate cancer subtypes to predict benefit from salvage treatment intensification.

A recent analysis of the NRG-RTOG 0534 "SPPORT" clinical trial evaluated the Luminal B (LumB) molecular subtype using the ...

Five-year phase 3 results support hypofractionated radiotherapy as a shorter treatment option after prostatectomy but raise concern about late GU toxicity.

Case report highlights the importance of a multidisciplinary, evidence-based approach to treating prostate cancer that ...

Men with high-risk prostate cancer have a higher likelihood of having residual disease following prostatectomy and may require radiation therapy after surgery, particularly when PSA levels begin to ...

The European PSA Screening Trial, Updated This update of the European PSA Screening Trial showed only a modest improvement in the numbers needed to screen and treat to prevent one death, with ...

A recent analysis of the NRG-RTOG 0534 "SPPORT" clinical trial evaluated the Luminal B (LumB) molecular subtype using the PAM50 genomic ...

Prostate cancer has a well-earned reputation for being one of the more trackable malignancies in medicine. Since the mid-1980s, a single blood test measuring prostate-specific antigen, or PSA, has ...

Blue Earth Diagnostics, part of the Bracco Group and recognized leader in the development and commercialization of innovative positron emission tomography (PET) radiopharmaceuticals, today announced ...